Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 2, 2001, Pages 502-508

  Polk, R E ^a   Brophy, D F ^a   Israel, D S ^a   Patron, R ^a   Sadler, B M ^a   Chittick, G E ^a   Symonds, W T ^a   Lou, Y ^a   Kristoff, D ^a   Stein, D S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 O DESACETYLRIFABUTIN; AMPRENAVIR; CYTOCHROME P450 3A4; DEACETYLRIFAMPICIN; DRUG METABOLITE; RIFABUTIN; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME INDUCTION; ERYTHROMYCIN BREATH TEST; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BIOTRANSFORMATION; BREATH TESTS; CARBAMATES; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DRUG INTERACTIONS; ERYTHROMYCIN; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; RIFABUTIN; RIFAMPIN; SULFONAMIDES;

EID: 0035141970     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.2.502-508.2001     Document Type: Article

References (38)

1. Clinical pharmacokinetics of rifampicin
2. Amprenavir
3. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers
4. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
5. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin
6. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors
7. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
8. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
9. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism
10. HIV-protease inhibitors
11. 14C N-methyl] erythromycin breath test in healthy male volunteers
12. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease
13. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers
14. Molecular and physical mechanisms of first-pass extraction
15. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents
16. Rifampin and rifabutin and their metabolism by human liver esterases
17. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
18. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
19. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P450 3A4/3A5: Mechanism-based inactivation of cytochrome P450 3A by ritonavir
20. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
21. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
22. Rifabutin: A review with emphasis on its role in the prevention and treatment of disseminated Mycobacterium avium complex infection
23. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects
24. Drug interactions in patients infected with human immunodeficiency virus
25. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men
26. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers
27. Dose-limiting toxicity of rifabutin in AIDS-related complex: Syndromes of arthralgia/arthritis
28. In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9
29. Clinical pharmacokinetics of rifabutin
30. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
31. Update on rifampin drug interactions, III
32. Metabolism of rifabutin and its 25-desacetyl metabolite, LM 565, by human liver microsomes and recombinant human cytochrome P-450 3A4: Relevance to clinical interaction with fluconazole
33. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients
34. CYP3A4 and the erythromycin breath test
35. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
36. Non-invasive tests of CYP3A enzymes
37. Short term effects of medications on CYP3A4 and P-glycoprotein expression in human intestinal mucosa
38. 14-C]-amprenavir in human volunteers